$30,000 of GRAIL INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to oncology and early multi-cancer detection, including diagnostics and screening."
You can find more data on corporate lobbying on Quiver Quantitative.
GRAL Insider Trading Activity
GRAL insiders have traded $GRAL stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $GRAL stock by insiders over the last 6 months:
- CHUN R DING has made 0 purchases and 3 sales selling 339,800 shares for an estimated $16,830,151.
- JOSHUA J. OFMAN (President) has made 0 purchases and 6 sales selling 162,876 shares for an estimated $8,391,292.
- ROBERT P RAGUSA (Chief Executive Officer) sold 94,035 shares for an estimated $3,190,607
- AARON FREIDIN (Chief Financial Officer) has made 0 purchases and 3 sales selling 50,027 shares for an estimated $1,735,741.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
GRAL Analyst Ratings
Wall Street analysts have issued reports on $GRAL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/03/2025
To track analyst ratings and price targets for GRAL, check out Quiver Quantitative's $GRAL forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
